Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Chief Scientific Officer | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,511 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Sale · Disposed 6,000 · Balance 86,511 F1: This transaction was executed in multiple trades at prices ranging from $38.87 to $38.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $38.87 to $38.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 30, 2026 20:57 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 6,000 | $38.88 | $233,280.00 |
DisclosureSEC source: 0001862458-26-000011 · wk-form4_1785445076.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,511 F1 · price: This transaction was executed in multiple trades at prices ranging from $38.87 to $38.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 13:04 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 636 | $23.78 | $15,124.08 |
DisclosureSEC source: 0001862458-26-000008 · wk-form4_1782997495.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,511 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:01 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 5,000 | $28.13 | $140,650.00 |
DisclosureSEC source: 0001862458-26-000006 · wk-form4_1779134506.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,875 Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 12:14 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 5,000 | $29.83 | $149,150.00 |
DisclosureSEC source: 0001862458-26-000004 · wk-form4_1773663272.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,875 F1 · price: This transaction was executed in multiple trades at prices ranging from $29.79 to $29.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 15,585 | $31.26 | $487,187.10 |
DisclosureSEC source: 0001862458-26-000002 · wk-form4_1772574768.xml · nonDerivative · entry 3 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,875 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 15,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001862458-26-000002 · wk-form4_1772574768.xml · nonDerivative · entry 2 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,460 F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 30,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001862458-26-000002 · wk-form4_1772574768.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,262 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 12:45 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 2,500 | $36.58 | $91,450.00 |
DisclosureSEC source: 0001862458-25-000003 · wk-form4_1754570700.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,872 Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 12:49 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 822 | $25.84 | $21,240.48 |
DisclosureSEC source: 0001323885-25-000080 · wk-form4_1751460544.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,372 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2025. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 2, 2025, which is the first trading day of the applicable offering period. The closing price on January 2, 2025 was $30.40. Read SEC document |
| May 28, 2025 Filed May 30, 2025 20:21 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 2,500 | $33.44 | $83,600.00 |
DisclosureSEC source: 0001323885-25-000071 · wk-form4_1748636330.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,550 Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:00 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 9,672 | $38.74 | $374,693.28 |
DisclosureSEC source: 0001323885-25-000023 · wk-form4_1741125647.xml · nonDerivative · entry 3 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,050 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:00 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 6,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-25-000023 · wk-form4_1741125647.xml · nonDerivative · entry 2 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,722 F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:00 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 19,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-25-000023 · wk-form4_1741125647.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,143 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:25 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 707 | $19.35 | $13,680.45 |
DisclosureSEC source: 0001323885-24-000097 · wk-form4_1719951914.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,784 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 28, 2024, which is the last trading day of the applicable offering period. The closing price on June 28, 2024 was $22.77. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:44 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 8,855 | $36.28 | $321,259.40 |
DisclosureSEC source: 0001323885-24-000033 · wk-form4_1709675052.xml · nonDerivative · entry 3 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,077 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:44 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 9,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-24-000033 · wk-form4_1709675052.xml · nonDerivative · entry 2 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,932 F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:44 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 19,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-24-000033 · wk-form4_1709675052.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,604 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 12:16 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 557 | $38.11 | $21,227.27 |
DisclosureSEC source: 0001323885-23-000081 · wk-form4_1688386579.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,310 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023, which is the first trading day of the applicable offering period. The closing price on January 3, 2023 was $44.84. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:11 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 4,793 | $38.81 | $186,016.33 |
DisclosureSEC source: 0001323885-23-000026 · wf-form4_167788145290873.xml · nonDerivative · entry 3 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,753 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:11 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 16,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-23-000026 · wf-form4_167788145290873.xml · nonDerivative · entry 2 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,546 F2 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:11 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 8,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-23-000026 · wf-form4_167788145290873.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,442 F1 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had both a Company performance goal and a service period requirement, which were both met. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:49 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 4,983 | $45.99 | $229,168.17 |
DisclosureSEC source: 0001323885-22-000108 · wf-form4_166362055231802.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,406 F1 · price: This transaction was executed in multiple trades at prices ranging from $45.97 to $45.99 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 350 | $34.73 | $12,155.50 |
DisclosureSEC source: 0001323885-22-000092 · wf-form4_165705258646144.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,389 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2022. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2022, which is the last trading day of the applicable offering period. The closing price on June 30, 2022 was $40.86. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:32 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 7,474 | $69.59 | $520,115.66 |
DisclosureSEC source: 0001323885-22-000027 · wf-form4_164634314104929.xml · nonDerivative · entry 3 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,039 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:32 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 6,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-22-000027 · wf-form4_164634314104929.xml · nonDerivative · entry 2 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,513 F2 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:32 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 7,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-22-000027 · wf-form4_164634314104929.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,688 F1 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had both a Company performance goal and a service period requirement, which were both met. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 13:39 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 24 | $59.10 | $1,418.40 |
DisclosureSEC source: 0001209191-22-000387 · doc4.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,899 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended December 31, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2021, which was the last trading day of the applicable offering period. The closing price on December 31, 2021 was $69.53. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:37 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 7,672 | $83.12 | $637,696.64 |
DisclosureSEC source: 0001209191-21-046673 · doc4.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.36 to $83.96 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:13 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 428 | $45.72 | $19,568.16 |
DisclosureSEC source: 0001209191-21-044939 · doc4.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,547 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021, which was the first trading day of the applicable offering period. The closing price on January 4, 2021 was $53.79. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.